BioCentury
ARTICLE | Company News

China exempts 12 cancer drugs from tariffs

September 20, 2019 9:05 PM UTC

China is exempting 12 cancer drugs from tariffs imposed on U.S. goods, the first time China has offered tariff relief since the trade war began last year.

The 12 drugs include Iressa gefitinib and Tomudex raltitrexed from AstraZeneca plc (LSE:AZN; NYSE:AZN); Xeloda capecitabine from Roche (SIX:ROG; OTCQX:RHHBY); Dacogen decitabine from Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan); Conmana icotinib from Beta Pharma (Princeton, N.J.); as well as floxuridine, cyclophosphamide, tegafur, ifosfamide, fludarabine, gemcitabine and cytarabine...